Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Universal Biosensors partners with Peter Mac for handheld cancer diagnosis device

  • In News
  • September 14, 2021
  • Alfred Chan
Universal Biosensors partners with Peter Mac for handheld cancer diagnosis device

A handheld device which can remotely diagnose the presence of cancer cells is on the horizon with biotech company Universal Biosensors (ASX: UBI) partnering with the Peter MacCallum Cancer Centre on the project. 

Under the agreement, Peter Mac will supply cancer patient samples to Universal Biosensors which will use the plasma samples in their trials for Tn Antigen from the handheld point-of-care cancer biosensor. 

Samples will include colorectal, breast and prostate cancer cells collected by Peter Mac and will be used by Universal Biosensors to validate the accuracy of Tn and determine the clinically relevant range of Tn concentrations.

“To be working with Peter Mac on the development of UBI’s handheld point-of-care cancer biosensor is very exciting for the Company,” said Universal Biosensors CEO, John Sharman. 

“The trial results and any subsequent development work, will form part of any regulatory application to have Tn approved for sale by regulators around the world. 

The device is not exactly new territory for UBI which already has other handheld biosensor devices available in the market, however this would be their first foray into cancer diagnostics. Their other devices are used for blood glucose testing and sulfur dioxide testing. 

Using real cancer cells for the testing of their cancer biosensor, UBI is aiming for the device to measure a patient’s cancer status initially seeking to identify remission and recurrence. The Company expects the device to be easier and cheaper to operate than current cancer diagnostic tools. 

“The blood testing market for cancer remission patients globally is AUD $17 billion per annum. Potentially the Tn biosensor may be used for early cancer diagnosis, disease staging and monitoring of treatment effectiveness,” said Sharman. 

Clinical trials of the device are expected to commence next month with UBI expecting to publish results in 2022. Following further refinement and applications for regulatory approval, the device could potentially be on the market as soon as 2024. 

For the Half Year ended 30 June 2021, Universal Biosensors reported a 219% increase in revenue to $3.4 million with a 29% improvement to their net loss after tax to $3.2 million. 

The strong jump in revenue resulted in UBI securing Sharman and his senior management team on long-term incentive deals which will be locked in until 2023. 

“I am extremely confident about the future of UBI and its prospects. We have a world class platform technology and significant opportunities in multiple markets which are deliverable. I am delighted to lock in a longer-term commitment to UBI and look forward to our collective success,” said Sharman. 

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  •  
  •  
  •  
  •  
  • asx ubi
  • cancer diagnostics
  • handheld biosensor
  • John Sharman
  • sulfur dioxide testing
  • UBI
  • universal biosensors
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.